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Lung cancer is the major cancer killer in the Western world, with the small cell lung 
cancer (SCLC) representing around 15–20% of all lung cancers. Extensive disease small 
cell lung cancer (ED SCLC) is found in approximately two-thirds of all cases, composed 
of both metastatic (M1) and non-metastatic (but presumably with tumor burden too 
large for locoregional-only approach) variant. Standard treatment options involve che-
motherapy (CHT) over the past several decades. Radiation therapy (RT) had mostly been 
used in palliation of locoregional and/or metastatic disease. In contrast to its established 
role in treating metastatic disease, thoracic RT (TRT) had never been established as 
important part of the treatment aspects in this setting. In the past two decades, thoracic 
oncologists have witnessed wide introduction of modern RT and CHT aspects in ED 
SCLC, which led to more frequent use of RT and rise in the number of clinical studies. 
Since the pivotal study of Jeremic et al., who were the first to show importance of TRT 
in ED SCLC, a number of single-institutional studies have reconfirmed this observation, 
while recent prospective randomized trials (CREST and RTOG 0937) brought more 
substance to this issue. Similarly, the issue of prophylactic cranial irradiation was inves-
tigated in EORTC and the Japanese study, respectively, bringing somewhat conflicting 
results and calling for additional research in this setting. Future studies in ED SCLC could 
incorporate questions of RT dose and fractionation as well as the number of CHT cycles 
and type of combined Rt-CHT (sequential vs concurrent).
Keywords: extensive disease, small cell lung cancer, thoracic radiotherapy, chemotherapy, prophylactic cranial 
irradiation
iNTRODUCTiON
Lung cancer is the major cancer killer in the Western world (1), with the small cell lung cancer 
(SCLC) representing around 15–20% of all lung cancers (2). While its incidence is declining in men, 
it continues to rise in women (3). In spite of significant efforts and refinements in staging system (4), 
division by “extensiveness” of the disease is still widely used. Extensive disease small cell lung cancer 
(ED SCLC) is found in approximately two-thirds of all cases, composed of both metastatic (M1) 
and non-metastatic (but presumably with tumor burden too large for locoregional-only approach) 
variant. Standard treatment options involve chemotherapy (CHT) over the past several decades (5). 
Various efforts to optimize treatment outcome with CHT, such as maintenance CHT or higher CHT 
doses unequivocally failed (6–10). With CHT, the median survival times (MST) are 9–12 months, 
while 5-year survivals of only 1–2% (9, 11–13).
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Radiation therapy (RT) had mostly been used in palliation 
of locoregional and/or metastatic disease. In contrast to its 
established role in treating metastatic disease, thoracic RT (TRT) 
had never been established as important part of the treatment 
aspects in this setting. This was largely due to conflicting reports 
in the past several decades about its usefulness in controlling 
intrathoracic tumor burden (14–17), and predominantly meta-
static nature of the disease. It is likely that inferior diagnostic and 
staging tool as well as outdated RT and CHT aspects such as 2D 
RT planning, modest RT doses, and non-platinum-based CHT 
significantly contributed to poor RT performance in this setting.
THORACiC RT
In the past two decades, thoracic oncologists have witnessed 
wide introduction of modern RT (3D planning, altered RT 
fractionation) and CHT (platinum-based) aspects in ED SCLC. 
This has resulted in more frequent use of RT and, importantly, 
rise in the number of clinical studies addressing the issue of 
optimization of treatment approaches by focusing on important 
aspects of RT.
The turning point in the history of modern treatment of ED 
SCLC occurred with the publication of seminal paper of Jeremic 
et al. (13) in 1999. It was the very first study which tested, in a 
prospective randomized Phase III fashion, standard treatment 
option (CHT) vs CHT and TRT, with a prophylactic cranial 
irradiation (PCI) given in both arms. This trial was based on 
observations from the past studies that, in ED SCLC, there were 
frequent intrathoracic failures, which also frequently occur even 
in patients who achieved initial complete response (CR) after 
CHT. Hence, study of Jeremic et al. (13) had its premises in the 
following: (1) significant proportion of patients with ED SCLC 
experience intrathoracic (locoregional) treatment failure, which 
cannot be successfully treated with second line CHT, (2) these 
failures may also become the source of subsequent metastatic dis-
ease (in patients with previous non-metastatic ED SCLC) and lead 
to death, (3) TRT could control intrathoracic tumor burden, (4) if 
successful, this may lead to improved and prolonged intrathoracic 
tumor control, and, if significant, may lead to an improvement 
in overall survival. Ultimate question, overshadowing all these 
considerations was: which subgroup of patients may have been 
suitable for testing the place and role of TRT in ED SCLC.
In the Jeremic trial (13), subjects were adult treatment-naive 
patients with good PS and biopsy-proven ED SCLC. All patients 
initially received three cycles of standard-dose cisplatin/etopo-
side (PE) regimen, after which complete patient reevaluation 
and restaging was performed both at local (intrathoracic) and 
the distant level. Randomization included only patients who 
achieved either a CR at both local and distant level, labeled as 
CR/CR or those who achieved a partial response (PR) within the 
thorax accompanied with the CR elsewhere (labeled as PR/CR). 
They received either accelerated hyperfractionated RT (Acc Hfx 
RT) and concurrent low-dose daily CHT, given on each RT day, 
followed by PCI, and then by additional two cycles of PE (group I) 
or four additional cycles of PE and PCI (Group II). Patients 
achieving worse response were not randomized. Total tumor dose 
was 54 Gy in 36 fractions, 1.5 Gy BID, while PCI dose was 25 Gy 
in 10 daily fractions. When deemed appropriate, palliative RT 
was given to patients with metastatic lesions with 30  Gy in 10 
daily fractions.
A total of 210 patients entered this study. TRT added to CHT 
offered superior outcome over CHT alone in terms of both the 
MST and 5-year survival rates [17 vs 11 months (p = 0.041), and 
9.1 and 3.7%, respectively]. Similar was observed for the local 
recurrence-free survival (the median time to local recurrence, 
30 vs 22 months, and 5-year local recurrence-free survival, 20 vs 
8.1%, respectively; p = 0.062), but RT added to CHT did not offer 
better distant metastasis-free survival (p = 0.35).
To enlighten the effects of TRT on local (intrathoracic) level, 
local CR rates were evaluated after three cycles of induction CHT 
at week 9 (i.e., just before the randomization), week 15 (i.e., when 
either Acc Hfx RT/CE in group I or 2 additional cycles of PE 
in group II were administered), and at week 21 (2 more cycles 
of CHT in each group). Local CR rate was similar after 9 weeks 
(47 vs 44%, p = 0.77), but after week 15, the local CR rate became 
significantly higher in group I than in group II (96 vs 61%, 
p = 0.000007). This was maintained at week 21 (96 and 66% for 
the two groups, respectively; p = 0.00005). Therefore, fourth and 
the fifth cycles of CHT barely improved response in group I once 
Acc Hfx RT/CE had been given. Similarly, the sixth and seventh 
cycles of PE in group II brought only a few percent increase in 
response rates. What these results imply is that perhaps one may 
not need more than 3–4 CHT cycles in this patient population, 
possible food for thoughts for future trials.
Jeremic et  al. (13) were the first to show that TRT plays 
indispensible role in the treatment of patients with ED SCLC 
after initial CHT. Beside primary study endpoints, an analysis of 
various pretreatment prognostic factors showed that higher KPS 
score and no significant weight loss were strong prognosticators 
of improved treatment outcome. As a potential guide for future 
studies, the number of metastases independently influenced 
survival. It was shown that metastatic tumor burden should 
be taken into account since patients with ≥2 metastases had 
significantly worse outcome than those with only one metastasis. 
Since approximately 90% of all patients in the study of Jeremic 
et al. (13) had 1–2 metastases, subsequent discussions in this field 
frequently labeled this disease extent as limited extensive disease.
Overall impact of the study of Jeremic et al. (13) was not easy 
to comprehend in the years following its publication. However, 
10 years after its publication, the study of Ou et  al. (18) retro-
spectively analyzed the data from several counties in southern 
California with estimated population of 6.2 million. Of a total of 
3,428 ED SCLC patients, RT was given to 1,204 (35.1%) patients. 
For this group, the 2-year, and MST were 9.3%, and 8 months, 
respectively, being significantly better than in those who did 
not receive RT (3.8%, and 4 months, respectively; p < 0.0001). 
Analysis of prognostic factors showed that delivered RT exerted 
independent and positive influence of on treatment outcome 
(p < 0.001).
A recent survey of 473 practicing US radiation oncologist 
attempted to identify the current pattern of practice of TRT in ED 
SCLC (19). In spite of great variation in the patient selection and 
doses of RT used, TRT was recommended after systemic CHT 
by 96% of the respondents. The type of the institution influenced 
TABLe 2 | Outcomes.
issue Jeremic et al. CReST Comments
Importance of 
improved LC
Yes Yes Leads to improved OS
Tempo of achieving 
improvement of LC
Faster Slower Leads to a faster  
improvement of  
OS in Jeremic et al.
OTT Shorter Longer Possible due to  
better patient  
characteristics in  
Jeremic et al.
Incidence of high-
grade toxicity
5% (lung) 20% 
(esophagus)
1.2% (lung) 
1.6% 
(esophagus)
Higher TRT doses and 
concurrent CHT in Jeremic 
et al.
Duration of CHT Shorter Longer Shorter appropriate in 
favorable patients?
LC, local control; OS, overall survival; OTT, overall treatment time; TRT, thoracic 
radiotherapy; CHT, chemotherapy.
TABLe 1 | Patient and treatment characteristics.
issue Jeremic et al. CReST
Less favorable patients 
(PS2)
0% 10%
Initial (pre-randomization)
CHT
3 cycles 6 cycles
TRT (dose/fx) 54 Gy/36fx
BID—Hyperfx
30 Gy/10fx
QD—Hypofx
CHT-TRT CHT followed by 
concurrent TRT-CHT
CHT followed by TRT (no 
concurrent part)
PCI—TRT PCI followed TRT-CHT Concurrent in almost 
90% pts
CHT, chemotherapy; TRT, thoracic radiotherapy; fx, fraction; BID, hyperfractionation 
(2 fx a day); QD, conventional fractionation (1 fx a day); PCI, prophylactic cranial 
irradiation.
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the decision with patients treated in private clinics being more 
likely to receive TRT than patients treated at academic centers 
(p = 0.0101). Interestingly, lower TRT recommended doses were 
associated with respondents claiming higher self-rated knowl-
edge of individual clinical trials.
Past several years also brought studies that investigated the 
same issue. In a prospective study from Canada (20), the median 
time to disease progression was 8.4  months and the MST was 
13.7 months. Additionally, two single-institutional, retrospective 
studies showed the same. In the Chinese study (21), for TRT-
treated group MST was 17.2  months, and 5-year survival was 
10.1%, respectively (p = 0.0001), while another Canadian study 
(22) reported on MST of 14 months and 2-year survival of 14% 
for TRT/CHT treatment.
Recently, in an EORTC (23) prospective phase III study 
patients with World Health Organization PS of 0 to 2 and confirmed 
ED SCLC without clinical evidence of brain, leptomeningeal, or 
pleural metastases, who achieved any response to 4–6 cycles of PE 
were treated with either TRT (30 Gy in 10 fractions) or no TRT, 
while all patients receiving PCI. Overall survival was longer in the 
TRT arm (p = 0.066), whereas 12-, 18-, and 24-month survival 
rates in the 2 arms were 33, 16, and 13% vs 28, 16, and 3%, respec-
tively. Although the trial was negative for the primary endpoint 
of 1-year overall survival, significance was achieved at 18 months 
(p = 0.03) and was maintained at 24 months (p = 0.004). MST 
from the time of randomization was 8 months, but when calcu-
lated from diagnosis, it was 12 months. Progression-free survival 
was longer in the TRT arm (p = 0.001). Intrathoracic progression 
(isolated or accompanied by progression elsewhere or as the first 
site of disease progression) was seen less frequently in the TRT 
arm. Almost a 50% reduction in intrathoracic recurrences (80 vs 
44%, respectively; p = 0.001) was observed.
Although EORTC study (23) characteristics (study design, 
patient eligibility, treatments offered) differed from those of 
Jeremic et al. (13) (Table 1), it is tempting to discuss and compare 
the two studies (Table 2) in order to obtain better perspective 
for future studies planning and execution. EORTC study (23) 
reconfirmed the importance of local control as initially sug-
gested by Jeremic et al. (13). However, more intensive TRT given 
with concurrent CHT in a shorter OTT in the study of Jeremic 
et al. (13) may have led to faster improvement in local control 
which, in turn, may have led to faster improvement in the overall 
survival. More intensive tumor cell kill was accompanied with 
somewhat higher incidence of acute toxicity, which in both 
studies was acceptable and, in the study of Jeremic et  al. (13), 
only high-grade acute esophageal toxicity was significantly more 
frequent in the TRT group. What this attempted comparison 
hints at is the large gap in both the patients’ and the treatment 
aspects when considering the two studies’ characteristics (13, 23) 
perhaps being at the two extremes, hence the necessity to fill in 
the existing gap with more clinical research.
One such attempt have been materialized in the Radiation 
Therapy Oncology Group study 0937 (24) during which patients 
with 1–4 extracranial metastases were deemed eligible after 
achieving either CR or PR to initial CHT. Patients received either 
PCI alone or PCI + TRT to the thorax and metastases. PCI was 
given with 25 Gy in 10 daily fractions in 2 weeks, while TRT was 
given with 45 Gy in 15 daily fractions in 3 weeks. Between March 
2010 and February 2015, a total of 86 patients were randomized. 
The study crossed the futility boundary for OS and was closed at 
planned interim analysis prior to meeting accrual target. With 
the median follow-up of 9 months, 1-year overall survival was 
similar between the groups: 60.1% (95% CI: 41.2–74.7%) for PCI 
and 50.8% (95% CI: 34.0–65.3%) for PCI + + TRT (p = 0.21). 
Three and 12-month rates of progression were 53.3 and 79.6% 
for PCI, and 14.5 and 75% for PCI + TRT. Time to progression 
favored PCI + TRT (p = 0.01). Not to be forgotten, there were 
some imbalances in the two groups, which might better explain 
the negative results for overall survival despite improvements in 
thoracic control, including the higher number of patients with PR 
vs CR to CHT and 2–4 vs 1 metastases in the group receiving RT. 
Treatment-related toxicity was also similar between the two arms. 
The authors concluded that overall survival exceeded predictions 
for both arms with the consolidative RT delaying progression but 
not improving the 1-year overall survival.
Although this trial will definitely be seen as a negative trial, it 
brought several important findings. The first site of failure after 
CHT is likely to be in sites of presenting disease; RT to these sites 
4Jeremic et al. RT in ED SCLC
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alters failure patterns; late RT without concurrent CHT is not 
durable; and, oligometastatic ED SCLC survival seems to again 
approach that of LD SCLC, confirming the postulates and results 
of Jeremic et al. (13). Ineffective RT dose and schedule, advanced 
age, and an imbalance in disease burden in the two groups all 
likely contributed to lack of survival advantage with consolidative 
RT in this trial. In addition, considering all trial aspects, authors 
suggested that perhaps a more appropriate treatment for this 
patient population with low volume systemic disease could have 
been early RT concurrent with cycle three or four of CHT in 
patients with a favorable response to cycles one and two of CHT 
followed by PCI, similar to the Jeremic trial (13).
PROPHYLACTiC CRANiAL iRRADiATiON
Contrary to the place and role of PCI in limited disease SCLC, 
where several PRCTs and MAs exist, in ED SCLC data concern-
ing it is much more limited. A large PRCT of EORTC included 
responders to 4–6 cycles of CHT (25). In this trial, patients 
were randomized to receive either PCI (20  Gy in 5 daily frac-
tions or 30 Gy in 12 daily fractions) or observation. PCI offered 
significantly lower cumulative risk of brain metastasis at 1-year 
(14.8 vs 40.4%, p <  0.001), which led to an improvement in 
the progression-free survival (14.7 vs 12  weeks, respectively, 
p = 0.02). Finally, PCI led to an improvement in 1-year overall 
survival (27 vs 13%, respectively, p = 0.003) as a consequence of 
improved CNS control.
The same EORTC trial (25, 26) collected self-reported patient 
data using both Quality of Life Questionnaire C30 and Quality 
of Life Questionnaire Brain Cancer Module while investigating 
the effect of PCI on quality of life (QoL). In the first report, side-
effects of PCI, including fatigue and hair loss, were significantly 
more severe in the group of patients receiving PCI (25). However, 
no significant differences were seen in the remaining endpoints. 
Importantly, in a subsequent report, there was a limited effect of 
PCI on these factors, none reaching the level of clinical signifi-
cance as (26). Severe worsening in global health status (35 vs 22%) 
from base line up to 3 months was observed in the PCI group; 
however, one must not forget that there was a 94% participation 
rate at baseline, followed by poor compliance during the follow-
up (60 and 55% at 6 weeks and 3 months, respectively). However, 
the control arm was significantly superior when an exploratory 
analysis of other symptom scale factors was performed.
These results have profoundly influenced the practice of RT 
in ED SCLC as PCI was overwhelmingly accepted as standard 
of treatment in this setting (5, 27). However, fresh data from a 
Japanese trial (28) seem to question that, in that trial, patients 
with any response to platinum-based doublet CHT and no 
brain metastases on MRI received PCI (25 Gy in 10 fractions) 
or observation. All patients were required to have brain MRI 
at 3-month intervals up to 12 months and at 18 and 24 months 
after enrollment. The primary endpoint was overall survival. 224 
patients were randomly assigned. In the planned interim analysis, 
of the first 163 enrolled patients, Bayesian predictive probability 
of PCI being superior to observation was 0.011%, resulted in early 
termination of the study because of futility. In the final analysis, 
the MST was 11.6 months in the PCI group and 13.7 months in 
the observation group (p = 0.094). The most frequent grade ≥3 
adverse events at 3 months were anorexia, malaise, and muscle 
weakness in lower limbs, which were all similar between the two 
groups. No treatment-related deaths occurred in either group.
While the Japanese study (28) reconfirmed the importance 
of CNS metastasis control, it failed to observe its influence on 
overall survival. Except, perhaps, fewer patients in that study, 
other possible reasons may exist as explanations for the exist-
ing discrepancy between Japanese (28) and EORTC (25) study. 
Japanese patients with ED SCLC were enrolled after they had 
been confirmed not to have brain metastases by MRI before 
randomization. By contrast, in the EORTC study (25), brain 
imaging at diagnosis was available in only 29% of randomized 
patients, while the proportion of patients who had brain imaging 
just before randomization was not stated. It is also very likely that 
in the EORTC study (25), some randomized patients actually 
had asymptomatic brain metastases before randomization since 
mandatory staging and follow-up procedures did not include 
brain imaging unless suggestive clinical symptoms were present. 
The longer overall survival reported by the EORTC study (25) in 
the PCI group might have reflected responses of asymptomatic 
brain metastases that had already been present before randomiza-
tion. Although observation group encountered higher incidence 
of brain metastases than the PCI group in the Japanese trial (28), 
this did not result in shorter survival in the observation group, 
which contrasts EORTC study (25) findings. Possible explana-
tion for this difference may be in difference in the proportion 
of patients who received subsequent treatment. Eighty-eight 
percent of patients in the PCI group and 89% of patients in 
the observation group received second-line CHT, however, 
more patients in the observation group received third-line or 
fourth-line CHT than did those in the PCI group. Additionally, 
in the Japanese study (28), anorexia, nausea, and malaise, which 
could be caused by CHT, were frequent and severe in patients 
in the PCI group beyond 3  months after randomization. The 
persistence of these adverse events, and the resultant impair-
ment in QoL during subsequent CHT, might have decreased the 
feasibility and tolerability of such treatment in the PCI group in 
that study. The PCI group and the observation group had similar 
overall survival probably because of this decreased feasibility and 
tolerability. Also, the higher frequency of brain metastases seen 
in Japanese study (28) is mainly attributable to the detection of 
asymptomatic brain metastases by MRI. Not to be forgotten, the 
difference in the proportions of patients who had subsequent 
therapy between the two studies is presumably because some 
patients with symptomatic brain metastases in the control group 
of the EORTC study (25) would not have had subsequent CNS 
RT or CHT because of deterioration in their general condition, 
whereas patients with asymptomatic brain metastases detected 
by MRI in the CREST study did receive both CNS RT and sub-
sequent CHT. Finally, the patients in the PCI group had more 
liver metastases, likely negatively to influence overall survival. 
Considering the impact of two studies on daily clinical practice, 
one may perhaps conclude that the Japanese study (28) may now 
slightly erode the firm position PCI had had in the past several 
years since the publication of the EORTC study (25) as “non-
believers” would now how have somewhat stronger rationale 
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against the use of PCI. It is reasonable to expect that these results 
would call for additional studies with more uniform diagnostic 
and follow-up criteria, including precise documentation of QoL 
aspects, which must take into account therapy administered at 
the time of CNS progression.
FUTURe TASKS
Research interests in the field of ED SCLC seem to have been 
revived in the past decade, after a dry decade post-Jeremic trial 
(13). Both PRCTs and single-institutional studies clearly show 
that thoracic oncologists understood the implication of the 
Jeremic trial (13). Indeed, in spite of CREST (23) and RTOG0937 
(24) controversies, more emphasis is and will be made on the 
place and role of RT in this setting, including employment of 
modern RT technologies (29). Future studies should address 
important RT-related (optimal TRT and extrathoracic RT 
dose/fractionation and its timing) and CHT-related questions 
(number of cycles and its concurrent vs sequential administra-
tion). They may include, but are not limited to the following: 
palliative vs curative TRT dose; sequential vs concurrent 
RT-CHT; concurrent RT-CHT at cycle 3 vs concurrent RT-CHT 
at cycle 5; total of 4 vs total of 6 cycles of CHT.
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